Brevan Howard Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Brevan Howard Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$600K	Sell	9,945 -2,096	-17%	-$116K	﹤0.01%	1355
2026 Q1	$700K	Buy	+12,041	New	+$555K	0.01%	1105
2025 Q1	–	Sell	-19,005	Closed	-$745K	–	1510
2024 Q4	$745K	Buy	19,005 +6,993	+58%	+$289K	﹤0.01%	509
2024 Q3	$473K	Buy	+12,012	New	+$484K	﹤0.01%	696

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Brevan Howard Capital Management's XENE Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 17% in Q2 2026, selling an estimated $116K and leaving 9,945 shares worth $600K. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Brevan Howard Capital Management first reported a position in XENE in Q3 2024 and has held it in 4 quarters since. The position peaked at $745K in Q4 2024. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Brevan Howard Capital Management held 9,945 shares of Xenon Pharmaceuticals worth $600K as of Q2 2026.
Brevan Howard Capital Management sold 2,096 Xenon Pharmaceuticals shares in Q2 2026, an estimated $116K.
Xenon Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1355 holding.
Brevan Howard Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
Brevan Howard Capital Management's Xenon Pharmaceuticals position peaked at $745K in Q4 2024.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.